AUS
NZ
UK
CA
USA
IND
Highlights:
Multiple ASX-listed healthcare firms initiate capital raisings to strengthen cash positions
EMVision showcases improved stroke diagnostic performance using AI at major health conference
Monash IVF updates FY25 outlook following operational challenges and market softness
Healthcare companies listed on the ASX 200 index witnessed notable activity this week, marked by an upswing in stock performance and a series of capital raisings. This surge comes as several firms within the sector push forward with clinical advancements and regulatory approvals, particularly in diagnostics and therapeutics.
Capital Raisings Highlight Sector Momentum
EBR Systems (ASX:EBR) confirmed commitments to raise funds through an institutional placement and an additional share purchase plan. This initiative supports the commercial rollout of its WiSE CRT system, a wireless solution for left-heart pacing, following its clearance by the US FDA.
Chimeric Therapeutics (ASX:CHM), with its focus on oncology and cell therapy, has secured commitments to progress its CAR T-cell therapy program targeting the CDH17 protein and to further its CORE-NK clinical study.
Recce Pharmaceuticals (ASX:RCE) completed a placement and entitlement offer to back its phase III trials for synthetic anti-infective treatments, aimed at positioning the company for potential commercial revenue in the coming years.
Island Pharmaceuticals (ASX:ILA) also finalized a placement to support the development of ISLA-101, intended for dengue fever treatment, with progress depending on data from the ongoing PROTECT clinical trial.
EMVision Advances Stroke Diagnosis Capabilities
EMVision Medical Devices (ASX:EMV) made strides in stroke diagnostics with enhanced performance of its AI-supported algorithm. Data presented at the European Stroke Organisation Conference revealed increased sensitivity and specificity in detecting ischemic cases using the emu RF-based model, compared to standard CT imaging.
The emu brain scanner is undergoing a pivotal trial to support regulatory clearance and further validation of the diagnostic algorithm’s performance. These advancements reinforce EMVision’s position in non-invasive stroke detection.
Monash IVF Lowers Earnings Forecast
Monash IVF Group (ASX:MVF) revised its FY25 profit expectations following soft market conditions and a recent incident involving a procedural error. The company attributed the earnings downgrade to weaker consumer sentiment, holiday timing, and industry dynamics, particularly in Victoria.
Analysts observed a downturn in domestic cycle volumes and ongoing competitive challenges. Key performance indicators such as new registrations and returning patients are under review, with further clarity awaited from an independent report concerning the procedural error.
Clarity Pharmaceuticals Commences Phase III Prostate Cancer Study
Clarity Pharmaceuticals (ASX:CU6) has begun a phase III trial named AMPLIFY to evaluate its diagnostic agent 64Cu-SAR-bisPSMA for identifying recurrence in prostate cancer cases. The trial spans multiple sites across the US and Australia and aims to generate data for regulatory submission.
This new study marks a continued expansion of Clarity’s clinical efforts and adds momentum to the broader diagnostic segment within the ASX 200 healthcare sector.
ResMed Faces Minimal Impact from Emerging Drug
ResMed (ASX:RMD) experienced a temporary dip in share price following top-line results from a phase III trial by Apnimed for an oral OSA treatment. Despite showing efficacy, the new therapy is not viewed as a major threat to ResMed’s CPAP offerings, particularly for patients with moderate to severe sleep apnea.
ResMed continues to benefit from product innovation, regulatory advantages, and trends in digital health technologies, securing its competitive stance within the respiratory health market.
